| Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
| Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More | Frank Vinluan | 04/26/19 | National |
| X4 Completes Reverse Merger with Arsanis, Looks Ahead to Phase 3 Test | Frank Vinluan | 03/13/19 | Boston |
| X4 Pharma Heads to Nasdaq Via Reverse Merger with Arsanis | Ben Fidler | 11/27/18 | Boston |
| Bio Roundup: ICER Eyes Cost, Azar at HHS, Gates’s ALZ Cash & More | Alex Lash | 11/17/17 | National |
| X4 Pharma Pulls In $27M for Immune Drug in Cancer, Rare Diseases | Frank Vinluan | 11/16/17 | Boston |
| Startup Builders, IPO Closers & More: Meet Xconomy’s CEO Award Finalists | Ben Fidler | 08/10/17 | Boston |
| Bio Leaders Mourn Passing of Genzyme Exec, Orphan Drug Innovator Termeer | Ben Fidler | 05/14/17 | Boston |
| Amylyx Nabs $5M to Take Aim at Nerve Cell Death in ALS Patients | David Holley | 08/22/16 | Boston |
| East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More | Ben Fidler | 09/04/15 | Boston |
| Ragan Reunites Ex-Genzymers at X4 Pharma to Battle Cancer | Ben Fidler | 09/01/15 | Boston |
| Stealthy X4 Pharma, Aided by Termeer, Other Ex-Genzymers, Nabs $37M+ | Ben Fidler | 09/01/15 | Boston |
